H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $35.00 price target on Agomab Therapeutics (NASDAQ: AGMB).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments